DBV Technologies S.A. (DBVT) Form 8-K — Jun 5, 2026
DBV Technologies has granted CEO Daniel Tassé 4,060,000 performance share units under a new 2026 Performance Share Unit Plan, with a grant date of June 5, 2026. The vesting of these units is strictly contingent upon achieving two specific FDA approval milestones for its lead product, Viaskin Peanut (VP), by July 1, 2028. Specifically, 2,900,000 units will vest upon the first FDA approval of a VP Biologics License Application (BLA), and an additional 1,160,000 units will vest upon a second FDA approval for a different indication or age group. If a single BLA covers both age groups, all units become eligible to vest, effectively treating the combined approval as satisfying both conditions.
Key figures
- Shares Offered
- 4060000
- Vesting deadline
- July 1, 2028
- First approval units
- 2900000
- Delivery installments
- 4
- Second approval units
- 1160000
Price after filing
Close on the filing date to close N calendar days later (from $17.58). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.